Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
california; jwci; sjci
PURPOSE: Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to androgen deprivation therapy (ADT) in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
METHODS: In this open-label randomized phase III study, patients with metastatic hormone-sensitive prostate cancer were randomly assigned 1:1 to ADT with orteronel (300 mg oral twice daily; experimental arm) or ADT with bicalutamide (50 mg oral once daily; control arm). The primary objective was the comparison of overall survival (OS), targeting a 33% improvement in median survival. A stratified log-rank test with a one-sided
RESULTS: Among 1,279 patients included in the analysis, 638 were randomly assigned to the ADT plus orteronel arm and 641 to the control arm. The median age was 68 years; 49% had extensive disease. After a median follow-up of 4.9 years, there was a significant improvement in PFS (median 47.6
CONCLUSION: The study did not meet the primary end point of improved OS with orteronel. The lack of correlation of PFS and PSA response with OS raises concerns over assumption of their consistent surrogacy for OS in the context of extensive postprotocol therapy in this setting.
Agarwal, Neeraj; Tangen, Catherine M; Hussain, Maha H A; Gupta, Shilpa; Plets, Melissa; Lara, Primo N; Harzstark, Andrea L; Twardowski, Przemyslaw W; Paller, Channing J; Zylla, Dylan; Zibelman, Matthew R; Levine, Ellis; Roth, Bruce J; Goldkorn, Amir; Vaena, Daniel A; Kohli, Manish; Crispino, Tony; Vogelzang, Nicholas J; Thompson, Ian M; and Quinn, David I, "Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)." (2022). Articles, Abstracts, and Reports. 6017.